NASDAQ$ARVN
Arvinas Inc. · Q4 2019 earnings
Q4 2019 earnings · · Investor relations
Briefing
Arvinas reported its Q4 and full year results, highlighting clinical and corporate advancements, including initial clinical data for ARV-110 and ARV-471, and a public offering that generated $107.6 million in net proceeds.
Arvinas reported a net loss of $21.0 million for the fourth quarter of 2019, compared to a net loss of $16.1 million for the same period in 2018. Revenue for the quarter was $4.9 million, up from $3.4 million in the prior year. The company's cash, cash equivalents, and marketable securities totaled $280.9 million as of December 31, 2019.
- Presented initial clinical data for ARV-110 and ARV-471, showing they were well-tolerated and safe for further development.
- Closed a public offering generating $107.6 million in net proceeds.
- Presented preclinical data demonstrating PROTAC® molecules degraded aggregates of human alpha-synuclein in primary rat neurons.
- Appointed Laurie Smaldone Alsup, M.D., to the board of directors.
Headline financials
Revenue & EPS history
Arvinas · Revenue · Quarterly
$4.89M
Revenue by segment
Arvinas · $4.9M total across 1 segment · Q4 2019
- Collaboration Revenue$4.9M—100.0%
Forward guidance
Arvinas expects to share Phase 1 dose escalation clinical data for ARV-110 in Q2 2020 and for ARV-471 in the second half of 2020. The company also anticipates providing information about the advancement of additional programs in its preclinical pipeline in the second half of 2020, and believes its current cash, cash equivalents, and marketable securities will be sufficient to fund operations into 2022.
Tailwinds
- Phase 1 dose escalation clinical data for ARV-110 expected in Q2 2020.
- Phase 1 dose escalation clinical data for ARV-471 expected in the second half of 2020.
- Information about additional preclinical programs expected in the second half of 2020.
- Cash, cash equivalents, and marketable securities expected to fund operations into 2022.
- ARV-110 and ARV-471 were well-tolerated and safe for further development.
Headwinds
- Uncertainties regarding the successful conduct of Phase 1 clinical trials for ARV-110 and ARV-471.
- Risk of not completing clinical trials for other product candidates.
- Uncertainty in receiving results from clinical trials on expected timelines, or at all.
- Risk that cash resources may not be sufficient to fund operating expenses and capital expenditure requirements.
- Dependence on successful development and regulatory status of product candidates.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2019
-2.4%
Avg return
Earnings day
-2.1%
Avg return
5 days after
-0.6%
Avg return
30 days after
30%
9 / 30 earnings
Positive
+11.8%
Q1 2019
Best reaction
-24.8%
Q1 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -4.4% | -10.2% | — | |
| Q4 2025 | +5.2% | +4.7% | -7.4% | |
| Q3 2025 | +0.5% | +17.3% | +34.1% | |
| Q1 2025 | -24.8% | -27.8% | -25.2% | |
| Q4 2024 | -6.8% | -3.5% | -54.9% | |
| Q3 2024 | -3.9% | -2.5% | -2.8% | |
| Q2 2024 | -1.0% | -7.0% | -6.3% | |
| Q1 2024 | +0.3% | -2.5% | -14.1% | |
| Q4 2023 | -5.8% | -3.1% | -15.4% | |
| Q3 2023 | -2.5% | -11.5% | +93.1% | |
| Q2 2023 | +2.1% | +6.8% | +12.8% | |
| Q1 2023 | +4.9% | +3.0% | -1.2% | |
| Q4 2022 | -7.0% | -10.8% | -23.0% | |
| Q3 2022 | -4.0% | +17.9% | -12.5% | |
| Q2 2022 | +3.8% | +4.5% | -19.3% | |
| Q1 2022 | -16.4% | -22.6% | -19.0% | |
| Q4 2021 | -2.6% | -4.4% | -5.4% | |
| Q3 2021 | +4.9% | +1.2% | -18.8% | |
| Q2 2021 | -4.3% | -8.9% | -13.4% | |
| Q1 2021 | -4.0% | -9.1% | -1.7% | |
| Q4 2020 | -1.0% | -8.0% | -15.6% | |
| Q3 2020 | -3.6% | +4.3% | +18.6% | |
| Q2 2020 | -5.0% | -11.1% | -23.0% | |
| Q1 2020 | -0.9% | -6.0% | -17.7% | |
| Q4 2019 | -3.2% | -1.8% | +14.2% | |
| Q3 2019 | +3.3% | +17.6% | +79.4% | |
| Q2 2019 | -4.6% | -0.2% | -1.5% | |
| Q1 2019 | +11.8% | +11.1% | +0.8% | |
| Q4 2018 | -3.0% | -6.9% | +42.9% | |
| Q3 2018 | -0.1% | +7.3% | -13.6% | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro